Dolores Hambardzumyan, PhD, MBA
img_Dolores Hambardzumyan
PROFESSOR | Neurosurgery
PROFESSOR | Oncological Sciences
Research Topics
Angiogenesis, Anti-Tumor Therapy, Bioinformatics, Blood-Brain Barrier, Brain, Brain Imaging, Cellular Immunity, Chemokines, Chemotaxis, Cytokines, Drug Resistance, Genomics, Knockout Mice, Microglia, Neurobiology, Neuroscience, Signal Transduction, Translational Research, Two-Photon Imaging
Multi-Disciplinary Training Area
Cancer Biology [CAB], Neuroscience [NEU]
Gliomas are the most frequently occurring primary brain tumor in children and adults. The most aggressive glioma subtype is the glioblastoma that remains amongst the deadliest form of human cancer. Glioblastomas are universally fatal, with a median survival of just over a year despite the most aggressive treatment regimens. Visit the Hambardzumyan Lab

PhD, National Academy of Sciences, Armenia

MBA, Emory University Goizueta Business School

Diploma of Education, Executive Coaching, Emory University Goizueta Business School

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Hambardzumyan has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.